• Vetiranary Medicine
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Researchers at UM find gene that causes death

November 1, 2004
Jessica Tremayne

ST. PAUL, MINN.-Researchers discovered the gene responsible for glycogen branching enzyme deficiency (GBED), which kill about one-fourth of foals born to carriers of the faulty make-up.

ST. PAUL, MINN.—Researchers discovered the gene responsible for glycogen branching enzyme deficiency (GBED), which kill about one-fourth of foals born to carriers of the faulty make-up.

Stephanie Valberg, DVM, PhD, led the research team at the University of Minnesota (UM) in identifying the GBE1 gene, which encodes the glycogen branching enzyme (GBE) involved in glycogen synthesis.

Dr. Stephanie Valberg visits a mother, Shena, and her new foal at the University of Minnesota&s College of Veterinary Medicine barn. Valberg is conducting several tests on neuromuscular issues in large animals.

Veterinary medicine researchers have been working to discover the cause of early death in foals for the past five years, but GBE1 has been difficult to pinpoint.

GBED occurs when horses that carry the recessive gene breed with another carrier, says Dr. Jim Mickelson, UM researcher and professor of veterinary bioscience. Quarterhorses and similar breeds run the greatest risk of carrying the defective GBE1 gene, but mixed breeds also run the risk of passing on the trait to their offspring.

Advertisement

The foal's deficiency is camouflaged by symptoms that resemble other equine neonatal diseases. Breeders often determine that foals' deaths are caused naturally instead of considering genetics as a probable cause, Mickelson says.

Foals that are born weak can die very soon after birth, or they can be nursed into health in the hospital, Valberg says.

"The foals seem to get stronger for a while and then die very suddenly," Valberg adds. "Other foals have spent much more time in the hospital and have progressively gotten weaker to the point where they can no longer stand up."

Weak foals lacked an enzyme required to form glycogen, the glycogen branching enzyme. Without glucose to metabolize energy, the foals were unable to survive more than two months.

"If owners of the majority of Quarterhorses have a planned breeding program to avoid carriers, the defective gene will eventually die out," says Valberg.

The discovery of the gene led to a new test that can screen horses for the trait before they are bred.

For $35 per horse, stallions and mares can be tested, sparing emotional and economic loss by a foal carrying the defective trait.

Blood samples, as well as mane or tail samples with intact roots, can be used for the test, Valberg says.

Ten percent of all Quarterhorses in the United States are carriers of the defective gene, Mickelson says. Approximately 50,000 horses a year could be affected by the gene, Mickelson adds.

"More than 300 tests have already been conducted," Valberg says.

The study was funded through the American Quarter Horse Association and the University of Minnesota Equine Center with funds provided by the Minnesota Racing Commission.

Editor’s Note: For more information, visit acadmec-server.cvm,umn.edu/neuromuscularlab/home.html


Advertisement

Latest News

Managing wounds in pet patients

Spectrum of care: protocols to support pet owners’ budgets

How to support women while still running a successful business

The Vets expands to Raleigh, NC

View More Latest News
Advertisement